Jonathan Allan's most recent trade in Stoke Therapeutics Inc was a trade of 72,000 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 18, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 72,000 | 72,000 | - | - | Employee Stock Option (Right to Buy) | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 48,000 | 48,000 | - | - | Restricted Stock Units | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 2,266 | 33,510 (0%) | 0% | 8.7 | 19,646 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 1,945 | 31,565 (0%) | 0% | 8.3 | 16,085 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,475 | 29,776 (0%) | 0% | 0 | Common Stock | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,475 | 14,950 | - | - | Restricted Stock Units | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 6,000 | 35,776 (0%) | 0% | 0 | Common Stock | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 6,000 | 18,000 | - | - | Restricted Stock Units | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.69 per share. | 09 Dec 2024 | 12,114 | 23,028 (0%) | 0% | 13.7 | 165,814 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 1,552 | 21,476 (0%) | 0% | 13.0 | 20,164 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 9,696 | 35,142 (0%) | 0% | 12.8 | 123,891 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 12,000 | 12,000 | - | - | Performance Stock Units | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 6,000 | 44,838 (0%) | 0% | 0 | Common Stock | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 6,000 | 6,000 | - | - | Performance Stock Units | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 33,927 | 38,838 (0%) | 0% | 0 | Common Stock | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 33,927 | 12,357 | - | - | Restricted Stock Unit (RSU) | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 8,599 | 25,801 | - | - | Stock Option (Right to Buy) | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 20 May 2024 | 8,599 | 2,598 (0%) | 0% | 15.0 | 129,327 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.07 per share. | 20 May 2024 | 8,599 | 11,197 (0%) | 0% | 7.1 | 60,795 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.19 per share. | 28 Mar 2024 | 5,026 | 2,698 (0%) | 0% | 13.2 | 66,287 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.81 per share. | 28 Mar 2024 | 100 | 2,598 (0%) | 0% | 13.8 | 1,381 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 36,000 | 36,000 | - | - | Employee Stock Option (Right to Buy) | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 24,000 | 24,000 | - | - | Restricted Stock Units | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 7,475 | 22,425 | - | - | Restricted Stock Units | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 7,475 | 10,073 (0%) | 0% | 0 | Common Stock | |
Stoke Therapeutics Inc | Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 2,349 | 7,724 (0%) | 0% | 6.1 | 14,326 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | General Counsel & Corp Sec | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 121,100 | 0 | - | - | Employee Stock Option (Right to Buy) | |
Stoke Therapeutics Inc | Allan Jonathan | General Counsel & Corp Sec | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
Stoke Therapeutics Inc | Allan Jonathan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 46,284 | 46,284 | - | - | Restricted Stock Unit (RSU) | |
Stoke Therapeutics Inc | Jonathan Allan | General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 13.48 per share. | 21 Jun 2023 | 1,948 | 0 (0%) | 0% | 13.5 | 26,252 | Common Stock |
Stoke Therapeutics Inc | Jonathan Allan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 44,800 | 44,800 | - | - | Employee Stock Option (Right to Buy) | |
Stoke Therapeutics Inc | Jonathan Allan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 29,900 | 29,900 | - | - | Restricted Stock Unit (RSU) |